RhumbLine Advisers’s MapLight Therapeutics MPLT Stock Holding History
Bought
Maintained
Sold
Other funds holding MPLT
BBA
RhumbLine Advisers's MPLT Position: Q3 2026 in Review
RhumbLine Advisers reduced its MapLight Therapeutics (MPLT) stake by 10% in Q3 2026, selling an estimated $29.9K and leaving 14,156 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #3402.
RhumbLine Advisers first reported a position in MPLT in Q4 2025 and has held it in 4 quarters since. The position peaked at $564K in Q2 2026. 98 funds tracked by Wall St. Rank hold MPLT as of Q3 2026.
- RhumbLine Advisers held 14,156 shares of MapLight Therapeutics worth $144K as of Q3 2026.
- RhumbLine Advisers sold 1,592 MapLight Therapeutics shares in Q3 2026, an estimated $29.9K.
- MapLight Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3402 holding.
- RhumbLine Advisers first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 4 quarters since.
- RhumbLine Advisers's MapLight Therapeutics position peaked at $564K in Q2 2026.
- 98 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.